Everand Logo

Welcome to Everand!

  • STAT

    Omeros defends its drug, but still won’t answer basic questions

    Omeros sought to defend its experimental drug OMS721 with a press release responding to my questions about the drug. But it didn't clear much up.
    by Adam Feuerstein Aug 23, 2017 2 minutes

    Omeros (OMER) on Wednesday sought to defend its experimental drug OMS721 with a press release responding to my story raising key questions about the drug.

    But it didn’t actually clear anything up.

    The Seattle biotech company is developing OMS721 to treat patients with rare blood ().

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
    New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

    Related Books & Audiobooks